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CASE REPORT
A case of Plasmodium malariae recurrence: 
recrudescence or reinfection?
Romualdo Grande1, Spinello Antinori2,3* , Luca Meroni3, Michela Menegon4 and Carlo Severini4
Abstract 
Background: Plasmodium malariae is the most neglected of the six human malaria species and it is still unknown 
which is the mechanism underlying the long latency of this Plasmodium.
Case presentation: A case of PCR-confirmed P. malariae recurrence in a 52-year old Italian man was observed 
5 months after a primary attack. In the interval between the two observed episodes of malaria the patient denied 
any further stay in endemic areas except for a visit to Libya, a country considered malaria-free. Genomic DNA of the P. 
malariae strain using five microsatellites (PM2, PM9, PM11, PM25, PM34) and the antigen marker of circumsporozoite 
(csp) was amplified and sequenced. Analysis of polymorphisms of the P. malariae csp central repeat region showed dif-
ferences between the strains responsible of the first and second episode of malaria. A difference in the allele size was 
also observed for the sequence analysis of PM2 microsatellites.
Conclusions: Plasmodium malariae is a challenging human malaria parasite and even with the use of molecular 
techniques the pathogenesis of recurrent episodes cannot be precisely explained.
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Background
Plasmodium malariae is the parasite responsible of quar-
tan malaria with the typical periodicity of fever paroxysm 
observed every 72-h as detailed in a study by Camillo 
Golgi in 1886, but also described in the fourteenth Cen-
tury by Dante Alighieri in the Divine Comedy (seventeen 
Canto of the Inferno) [1–3]. The parasite is widely distrib-
uted in most tropical and sub-tropical areas, with over-
lapping presence with Plasmodium falciparum, especially 
in sub-Saharan Africa, where it might easily be over-
looked if molecular techniques such as polymerase chain 
reaction (PCR) are not used for diagnosis [1, 4]. Although 
it is well known that malaria episodes due to P. malariae 
can occur even after 30–50  years following a previous 
malaria attack, the mechanism responsible for its persis-
tence and late recurrence still remains a medical mystery 
[5–8]. The failure to identify hypnozoites in liver biopsy 
of either human and animals is considered a proof that 
P. malariae is not a relapsing Plasmodium species, thus 
still giving the Bignami’s interpretation of endo-eryth-
rocytic persistence of the parasite as the more satisfac-
tory [3, 8–10]. However, the fact that the existence of P. 
malariae hypnozoites has never been proven is not “per 
se” a proof against it. For instance Plasmodium ovale is 
credited to produce hypnozoite although P. ovale hypno-
zoites have never been demonstrated biologically. Herein 
it is described a case of P. malariae infection in an Italian 
man occurring 5 months after a previous malaria episode 
despite the fact he had not travelled to a malaria-endemic 
region. A review of similar cases is also described 
together with possible explanation of this phenomenon.
Case presentation
A 52-year-old Italian man sought care at the Emergency 
Department (ED) of Luigi Sacco Hospital in Milan, Italy 
on 14 December, 2017, complaining of a quartan pat-
tern of fever that started 1  week before together with 
arthralgia and myalgia. He reported frequent trips to 
sub-Saharan Africa, the last one to Mozambique and 
several previous malaria attacks treated by himself using 
quinine. He reported to have not taken anti-malarial 
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chemoprophylaxis. A chest X-ray was negative and 
laboratory examinations were unremarkable except for 
an increase of C reactive protein (50.9  mg/L) and mild 
thrombocytopaenia (153,000/µL). A blood smear was 
negative for malaria parasites as well as a rapid diagnostic 
test (RDT), but species-specific PCR turned positive for 
P. malariae. He was treated with a standard regimen of 
oral chloroquine phosphate (1 g per os initially, 500 mg 
6 h after the first dose, and then 500 mg once a day on 
the 2nd and 3rd days of therapy). Subsequently he was in 
good health until the end of April when fever recurred 
spiking to 40  °C associated with severe headache. On 
4 May, 2018 he presented to the ED of another hospi-
tal where a blood smear was positive for trophozoites 
of Plasmodium spp. He was transferred to the ED of L. 
Sacco hospital where a new blood smear showed scanty 
trophozoites of P. malariae; RDT was negative and spe-
cies-specific PCR confirmed the diagnosis of P. malariae. 
Clinical examination was remarkable for the presence 
of herpes labialis, but otherwise negative. A chest X-ray 
was negative and blood examinations showed increase 
C-reactive protein (201 mg/L) mild anaemia (Hb 12.2 g/
dL, Ht 35%), leukopaenia (WBC 3200/μL) and thrombo-
cytopaenia (45,000/μL). In the period between the two P. 
malariae episodes he admitted only a short stay in north-
ern Africa (Libya) without any other trip to sub-Saharan 
Africa. He was admitted to the Infectious Diseases Ward 
and treated with a 3-day course of dihydroartemisinin–
piperaquine (320/40 mg) 4 tablet/day for 3 days. He was 
discharged on 8 May, 2018 with negative blood smear 
and PCR for malaria. On follow-up he had normalization 
of blood examinations and up to January 2019 no more 
recurrences of malaria.
Methods
Plasmodium malariae genomic DNA was extracted from 
200  μL of whole infected blood samples collected from 
the patient at both hospital admittances, using PureLink 
Genomic DNA Kit-Invitrogen. Five microsatellites (MSs) 
(PM2, PM9, PM11, PM25, PM34) and the antigenic 
marker P. malariae circumsporozoite (Pmcsp) gene were 
genotyped, by PCR amplification and sequencing, in P. 
malariae isolate(s) responsible for the patient’s infection 
in order to compare the primary infection and the second 
episode.
Microsatellite amplification was performed using spe-
cific primers previously described by Bruce et  al. [11], 
adopting slight modifications in the amplification pro-
tocol (Table  1). For amplification of Pmcsp gene, two 
internal primers were designed specifically and used to 
amplify the central repeat region of the gene (Table  1). 
All PCR products were examined by gel electrophoresis 
and sent to Eurofins Genomics Company (Germany) for 
sequencing. The obtained sequences were compiled and 
analysed by Accelrys DS Gene Software.
Comparison of the genetic diversity of P. malariae iso-
lates collected from the patient’s two blood specimens 
collected on first hospital admission (14 December, 2017) 
and on second admission (5 May, 2018) was performed 
by direct sequencing of the amplified fragments of six P. 
malariae molecular markers.
A PubMed, Scopus and EMBASE literature search 
was performed from 1940 to 2018 with the search terms 
P. malariae AND “recrudescence” AND “recurrence” 
AND “relapse”. Several cases were added by cross-ref-
erencing the articles cited in the retrieved case reports. 
Articles in Chinese, Russian and Japanese languages 
were excluded.
Results
In each of two tested DNA samples, a single amplified 
product was observed on agarose gel for each analysed 
target, suggesting the presence of a single detectable iso-
late for each malaria episode. The central region of Pmcsp 
gene and three MSs (PM2, PM9, PM34) were successfully 
sequenced in patient’s two blood specimens. The result of 
the sequencing of PM11 and PM25 showed the amplifi-
cation of non-specific bands, resulting in a cross-reaction 
with human DNA, and for this reason these two molecu-
lar markers were excluded by the present analysis.
Analysis of polymorphisms of the Pmcsp central repeat 
region resulted in the amplification of a DNA fragment 
of 864 base pairs (bps) (288 aminoacids) in the isolate 
responsible of the first episode, with a repeat region char-
acterized by two NDAG tetrapeptide repeat units fol-
lowed by 51 NAAG tetrapeptide repeat units. The isolate 
Table 1 Primers and cycling parameters for PCR
Primers Aminoacids PCR cycling 
parameters
Pm09for ACG ATA ATA ATA TAA ATG GGG 94 °C-30 s, 
45 °C-30 s; 
72 °C-1 min, 40 
cycles
Pm09rev GTT CAT AAC TTT GAT CTT AAC 
Pm11for GGG ATA TGA ATT ACA TAC AC
Pm11rev CTT TAT TTG TGG TCG AGG 
Pm25for CCA AAT AAG TGA CAT ACA AC
Pm25rev GAG GTA ACT TAA AAA ATT CAC 
Pm02for GGG GCA TAA AGG AAA AAC 94 °C-30 s, 
52 °C-30 s; 
72 °C-1 min, 40 
cycles
Pm02rev GAA TTT TTG AAT AAC AAG AAA CC
Pm34for GAA TGG AAA AAT TCC TTC AG
Pm34rev TTG GAC AAT GAA AAA ACT AAG 
Pm MSP1for TTC CAA AAA TTG AGG AAA TGT T
Pm MSP1rev TTT GGA CAA TGT CGG AAC AA
Pm CSfor CCC ACA AAA GCT GTT GAA AA
Pm CSrev TGG TGA CCA TTC CTC CGT A
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collected from the second episode had a more complex 
structure of the central repeat region  (NDAG3 + NAAG 
1 + NAAG 5 + NDAG1 + NAAG 9 + NDAG1 + NAAG 20) 
for a total length of 816 bps (272 aminoacids) (Fig.  1; 
Additional file 1: Figure S1).
The sequence analysis of PM2 displayed two different 
size variants: P. malariae isolate collected in December’s 
specimen had an allele size of 192 nucleotides (nts) due 
to a repeat unit region of 68 nts; instead, the second iso-
late collected in the second hospital admission showed an 
allele size of 216 nts with a repeat region of 92 nts (Fig. 2: 
Additional file  2: Figure S2). However, both P. malariae 
isolates collected from the patient displayed the same 
allele for PM9 (439 nts in size) and PM34 microsatellites 
(295 nts).
Review
Twenty-three case reports of P. malariae recrudescence 
were retrieved from the literature and are summarized 
in Table  2 [5–7, 12–31]. However, it is plausible that 
very ancient case reports written in languages other than 
English were overlooked by this research by the fact that 
they are not included in modern databases. The oldest 
retrieved report about late P. malariae recrudescence 
was published by Shute in 1944 in The Lancet and the 
same author in a review regarding imported malaria in 
the UK cited another two observed cases occurring after 
10 and 15 years [12, 32].
In the oldest cases recorded the diagnosis of P. malar-
iae infection was based on microscopy only and the 
long latency before the recrudescence was inferred by 
the notion about elimination of malaria in the country 
of origin or by the last time in which the patients lived 
in or travelled to an endemic area [5, 6, 12–17, 19–21]. 
No difference of gender was observed in the cases 
reported in the literature and the median age of patients 
was 59  years. A quartan fever paroxysm was reported 
in 73.3% of described cases for whom this information 
was available (11/15) [6, 7, 13–15, 17–19, 26]. Malaria 
was acquired in Europe (before its elimination) in 7 
cases, in sub-Saharan Africa in 11 cases, in Southeast 
Asia in 3 cases, and in Trinidad in the remaining case. 
The attack of malaria was precipitated by surgery in five 
patients (splenectomy in 3 cases), and immunosuppres-
sive therapy in 2 patients [5–7, 15, 17, 19, 21]. An epi-
sode of falciparum malaria preceded the recrudescence 
by P. malariae in 4 patients consistent with the possibil-
ity of initially overlooked mixed infections [18, 22, 23, 
25]. Six patients had a documented episode of malariae 
malaria 4  weeks to 25  months before the diagnosis of 
recrudescence [26–31]. Splenomegaly was documented 
in 9 patients (36.4%) and in two cases splenectomy was 
Fig. 1 Amino acid sequence alignment of a portion of repeat region of csp gene of P. malariae isolates analyzed in the present study (Isolate 
14-12-17, from first hospital admission; Isolate 05-05-18, from second hospital admission) and of a P. malariae isolate from an imported malaria case 
(P. malariae clinical strain)
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undertaken as diagnostic evaluation [5, 6, 14, 18–21, 
31]. At the time of P. malariae recrudescence diagnosis, 
a nephritic syndrome was observed in two patients [21, 
24]. Chloroquine was the drug most frequently employed 
for treatment (12 patients, 52.2%) followed by quinine (4 
patients) [6, 7, 13–15, 19–21, 23, 25–31].
Discussion
Plasmodium malariae is the most neglected among Plas-
modium species responsible of human malaria, being fre-
quently undetected due to the very low parasitaemia it 
causes. Only recently a draft nuclear genome and a high-
quality reference genome of P. malariae have been made 
available but nevertheless this Plasmodium remains the 
most mysterious among human malaria parasites and its 
long-term persistence has so far been elusive to any con-
vincing explanation [33, 34]. Moreover, the existence 
among African apes and New World monkeys of two very 
similar species based on morphologic characteristics (i.e., 
Plasmodium rhodaini and Plasmodium brasilianum) has 
raised the question whether P. malariae should be consid-
ered a zoonosis, an anthroponosis or as inferred by Lalrem-
ruata et  al., at least in South America, P. malariae and P. 
brasilianum are a single anthropozoonotic species [35–37].
Recurrences of P. malariae infection even after more 
than 50  years of latency have been described in old 
malaria literature (Table 2) but the availability of molec-
ular biology techniques nowadays allowed a better 
classification of such episodes as a consequence of recru-
descence or re-infection [5–7, 12–31].
Herein it is described a case of an Italian man who 
presented two symptomatic PCR-confirmed episodes 
of P. malariae infection occurring 5  months apart. His 
medical history was notable for several previous epi-
sodes of malaria acquired during his frequent travels to 
sub-Saharan Africa, usually with self-treatment with qui-
nine. In the interval between the two observed episodes 
of malaria the patient denied any further stay in endemic 
areas except for a visit to Libya, a country considered 
malaria-free, thus giving the hypothesis of a recrudes-
cence as the most plausible. Interestingly, genotyping of 
four P. malariae specific genetic markers indicated sub-
stantial genetic diversity of the two P. malariae strains 
responsible for the first and the second malaria episode. 
In this context the possibility of a de-novo infection 
acquired in Libya cannot be discarded and the recent 
description in Italy by Martelli et al. [38] of two Malian 
immigrants diagnosed with falciparum malaria in Italy 
after a long stay (3 to 5 years) in Libya might be concord-
ant with this hypothesis.
Alternatively, in the case of recrudescence, one can 
consider the possibility of chloroquine-resistance or 
inadequate drug concentration. To the best of knowl-
edge clinical chloroquine-resistant P. malariae has been 
reported only in a study conducted in Indonesia and in 
a single anecdotal case acquired in Africa [28, 39]. In the 
former study one patient had persistent parasitaemia 
on day 28 and two had persistent parasitaemia on day 
8. However, Collins and Jeffery retrospectively analysed 
the curve of clearance of P. malariae among neurosyphi-
lis patients infected with P. malariae and subsequently 
treated with chloroquine and showed that an extended 
clearance time is frequent with this species, concluding 
that is not indicative of resistance to chloroquine [40].
Fig. 2 Nucleotide sequence alignment of PM2 microsatellite of P. malariae isolates analyzed in the present study (Isolate PM 14-12-17, from first 
hospital admission; Isolate PM 05-05-18, from second hospital admission) and of a P. malariae isolate from an imported malaria case (P. malariae 
clinical strain)
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However, recurrence of P. malariae in cases of mixed 
malaria infections in which P. malariae was initially 
overlooked and the patients were treated for P. falcipa-
rum infection with mefloquine, halofantrine, quinine, 
or artemether/lumefantrine (AL) have been previously 
reported [18, 22, 23, 28]. More recently, Rutledge et al. [30] 
described a late recrudescence of P. malariae in which the 
minority initial subpopulation survived after treatment 
with AL and they postulated the need to use artemisinin 
combination therapy (ACT) with long half-life partner 
drug and longer follow-up of patients with P. malariae. 
Another possibility to be investigated as proposed for 
P. falciparum is the sequential use of two artemisinin-
based combination regimens [41]. As far as the described 
patient, although the malaria infection was acquired in 
Africa where a single possible P. malariae chloroquine-
resistant episode has been described, the decision was 
to treat the second episode of malaria with dihydroarte-
misinin–piperaquine (DHP) with no malaria recurrence 
after 8 months of follow-up [26]. However, given the long 
latency described for P. malariae infections it is pres-
ently unknown for how long a patient should be followed 
and, in clinical practice, among travellers with imported 
malaria follow-up longer than 4  weeks seems unfeasible 
[5–7, 12–17, 19–21, 23]. More recently, in a study aimed to 
investigate the biological basis of breakthrough P. malariae 
among travellers using atovaquone–proguanil chemo-
prophylaxis, Teo and co-workers showed the absence 
of mutation in the parasite locus pmcytb associated with 
recrudescence of P. falciparum [42]. These investigators 
hypothesized again the possibility that P. malariae is a 
relapsing parasite with the capacity to undergo latent hyp-
nozoites in the liver responsible of new erythrocytic sexual 
replication years after the initial infection. Based on the life 
span of erythrocytes (110 days) and of hepatocytes (150–
300 days), Richter et al. [43] concurred with the hypothesis 
of the liver as the possible reservoir of P. malariae. How-
ever, Garnham, based on several observations concluded 
that “P. malariae are recrudescences of persisting blood 
forms of the respective parasites” [3, 8, 44].
Moreover, it is hard to explain how a dormant liver 
parasite is responsible of malaria transmitted by blood 
transfusion by an asymptomatic blood donor as long 
as 44 years after the last exposure in a malaria endemic 
area [45–47]. The interesting report by Rutledge and co-
workers who showed that the recrudescent isolate in the 
patient they described was a single clone present at low 
density in the initial P. malariae infection, raised also 
the possibility that this patient harboured several differ-
ent population of P. malariae acquired at different time 
frames with different fitness to anti-malarial drugs, one 
of which was capable of emerging when the susceptible 
ones were eliminated [30].
The review of the literature confirms the importance of 
immunity in controlling long-term latency of P. malariae 
with a state of balanced parasitism which can be abruptly 
broken by stress events, such as surgery or removing the 
spleen or by treatment with immunosuppressive drugs, 
each one responsible for recrudescence of malaria [5–7, 
15, 17, 19, 21]. However, the precipitating event in several 
other cases remain unexplained [12–14, 16, 18, 20, 22–31]. 
Also intriguing is the ability of P. malariae to escape drugs 
which are blood schizontocidal for P. falciparum despite the 
very low parasitaemia that the former parasite produces. It 
can be speculated that in view of the long pre-patent period 
of P. malariae the duration of therapy against this Plasmo-
dium should be increased and when using an artemisinin 
combination, as suggested by Rutledge et al., a partner drug 
that is slowly eliminated should be preferred [30, 33].
Conclusion
It is described a case of probable P. malariae recru-
descence, together with explaining hypothesis and a 
review of the literature of long-latency recrudescences. 
One-hundred and sixty-five years after its description 
P. malariae remains the most mysterious of the human 
malaria parasites and as suggested by Shute “it provides 
an almost perfect example of successful parasitism, with-
out the frequent change of host need by other species of 
human malaria” [12]. Several recent thorough reviews 
about P. malariae persistent parasitism take again the 
hypnozoite hypothesis based on the fact that the “not 
proven existence” (as for P. ovale) should not be consid-
ered as proof for the non-existence of P. malariae hypno-
zoites and the need to search for an alternative place of 
dormancy, such as the spleen [25, 43, 48–50].
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